GCM
LUCD icon

Ghisallo Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Ghisallo Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,960,066
Closed -$2.99M – 234
2025
Q3 		$2.99M Buy
+2,960,066
New +$3.23M 0.1% 156
2025
Q2 		– Sell
-422,004
Closed -$629K – 191
2025
Q1 		$629K Buy
+422,004
New +$506K 0.05% 98

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ghisallo Capital Management's LUCD Position: Q4 2025 in Review

Ghisallo Capital Management sold out of Lucid Diagnostics (LUCD) in Q4 2025, closing a stake of 2,960,066 shares — an estimated $2.99M sold.

Ghisallo Capital Management first reported a position in LUCD in Q1 2025 and held it in 2 quarters. The position peaked at $2.99M in Q3 2025. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

  • Ghisallo Capital Management reported no remaining Lucid Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Ghisallo Capital Management sold 2,960,066 Lucid Diagnostics shares in Q4 2025, an estimated $2.99M.
  • Ghisallo Capital Management first reported a position in Lucid Diagnostics in Q1 2025 and held it in 2 quarters.
  • Ghisallo Capital Management's Lucid Diagnostics position peaked at $2.99M in Q3 2025.
  • 89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Ghisallo Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.